-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $55

Benzinga·10/29/2025 18:09:12
Listen to the news
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $45 to $55.